Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Abstract Text:

    jessica bellJessica Bell,cassandra moranCassandra Moran,julie blattJulie Blatt,jessica bellJessica Bell,cassandra moranCassandra Moran,julie blattJulie Blatt,jessica bellJessica Bell,cassandra moranCassandra Moran,julie blattJulie Blatt,

    Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab. Pediatr Blood Cancer 2008;50:370-371. (c) 2006 Wiley-Liss, Inc.

    Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Publishing Authors By Initials

    j bellJ Bell,c moranC Moran,j blattJ Blatt,j bellJ Bell,c moranC Moran,j blattJ Blatt,j bellJ Bell,c moranC Moran,j blattJ Blatt,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Pediatric blood & cancer

    VOLUME: 50

    Page Numbers: 370-1

    Journal Abbreviation:

    ISSN: 1545-5017

    DAY: 12

    MONTH: Feb

    YEAR: 2008

    Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 101186624

    Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.

    AFFILIATION: Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Pediatr Blood Cancer

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News